Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

E. R. Squibb Sons, Inc.

Université Louis Pasteur

Other

Andree Dierich

Marianne Lemeur

Pierre H Chambon

Philippe Kastner

Manuel Mark

David Lohnes

Cathy Mendelsohn

Philippe Gorry

Thomas Lufkin

Hans W D Matthes

Brigitte Kieffer

Frederic Herve Simonin

The invention concerns the use of a non-human transgenic mammal whose expression of a gene coding for an opiate receptor is modified, particularly in the nerve tissues with respect to a normal expression, in particular in the nerve tissues, for producing a medicine for the treatment of pathological conditions involving opiate receptors, in particular severe acute or chronic pains, drug addiction or the prevention or the treatment of transplant rejections.

Transgenic animal whose expression of the opiate receptors is modified

The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, to mice heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptors, or the normal expression thereof, is desirable.

Genetically engineered mice containing alterations in the genes encoding retinoic acid receptor proteins

Genetically engineered mice and cell lines containing alterations in the

Genetically engineered mice containing alterations in the genes encoding

Growing community of inventors

Strasbourg, France

Andree Dierich